Somnomed Limited · ASX:SOM
Somnomed — Shareholder Meeting (November 2021)
18 slides from Somnomed's shareholder meeting presentation, Nov 25, 2021
Slide 1: Chairman's AGM address by Guy Russo
For personal use only The Manager Company Announcements Office Australian Securities Exchange Limited 20 Bridge St Sydney NSW 2000 Chairman’s AGM address by Guy Russo 2021 Annual General Meeting 25 November, 2021 Dear Shareholders It is an honour to address you today as your Chairman. It has now bee
Slide 2: Chairman's address (continued)
Neil and his team continue to work tirelessly to promote stronger clinical guidelines, as well as investing in and supporting clinical research, which validates our treatment option. The number of patients throughout the world treated with a SomnoDent® device surpassed 650,000 recently, while the co
Slide 3: Managing Director's address by Mr Neil Verdal-Austin
Managing Director’s address by Mr Neil Verdal-Austin 2021 Annual General Meeting 25 November, 2021 For personal use only It is indeed an honour to address you today and provide you with an update on the business. It is now three years ago that I was appointed as your CEO and we began a new journey f
Slide 4: Managing Director's address (continued)
Secondly, I would now like to turn to the future of our Company. SomnoMed has an exciting and long-term opportunity to invest in a transformational technology to build on its competitive advantage. We are now at the start of this journey. While we always focus on our treatment offering and the inves
Slide 5: Treatment focused. Technology driven.
For personal use only AGM Presentation 25 November 2021 Treatment focused. Technology driven. Financial results are unaudited
Slide 6: SomnoMed's Vision/Mission
SomnoMed’s Vision/Mission For personal use only Our vision is to lead in the treatment of patients suffering from obstructive sleep apnea and relevant adjacent conditions Our mission is to advance the adoption, acceptance and treatment of oral sleep apnea therapies by medical specialists, dentists,
Slide 7: Highly experienced and supportive board of directors
Highly experienced and supportive board of directors For personal use only Guy Russo Michael Gordon Karen Borg Non-Executive Chairman Amrita Blickstead Non-Executive Non-Executive Non-Executive Highly accomplished business Currently CFO of Rokt, Currently CEO of Healthdirect leader with strong comme
Slide 8: Passionate and driven management team
Passionate and driven management team For personal use only Hervé Fiévet Neil Verdal-Austin Mark Harding CFO CEO Senior VP, Global Marketing Joined SomnoMed in April 2019 27+ years experience with various Joined SomnoMed in July 2019. Extensive experience in all aspects medical device , distribution
Slide 9: Significant addressable markets globally
Significant addressable markets globally Obstructive sleep apnea, a growing burden on the medical system affecting a significant portion of the population For personal use only Obstructive sleep apnea (OSA) is a disorder that occurs when a person’s breathing is interrupted during sleep because the a
Slide 10: The SomnoMed product difference
The SomnoMed product difference For personal use only SomnoMed delivers the highest level COAT™ comfort and quality Technologically Advanced Cost Effective Solution Materials that improve patient comfort and Lower cost to fit, maintain and retain customers product function for sleep physicians, dent
Slide 11: Improving treatment effectiveness for OSA patients
Improving treatment effectiveness for OSA patients For personal use only Efficacy Many patients Clinical Insight don’t get effective The findings are sobering. Our CPAP: treatment all data suggest that despite Lower Compliance night, every night numerous changes to machine x Greater Efficacy and mas
Slide 12: Positioned for future growth
Positioned for future growth For personal use only Technology driven Investment in the technology pathway to unlock true COAT™ potential Best in class service and technical support Growing and extensive sales and distribution footprint in both dental and medical channels Treatment focused Design and
Slide 13: Growing the sector through positioning the patient's alternative
Growing the sector through positioning the patient’s alternative For personal use only • Show Sleep Physicians how COAT™ and CPAP can be equally effective over a Effectiveness patient’s full night of sleep Equation • Focus is on superior compliance of COAT™ and patient preference for COAT™ • Fund an
Slide 14: Investing to achieve category leadership
Investing to achieve category leadership Financial framework for future growth and profitability For personal use only Accelerated Balanced Mature growth growth growth invest EBITDA1 Top & bottom Priority Top line Bottom line line into future horizons Annual revenue >20% 15-20% 10-15% growth to Main
Slide 15: SomnoMed future horizons
SomnoMed future horizons For personal use only Building Creating Driving Investing in Awareness Advancing + Acceptance Positioning + Adoption Continued + Innovation Transformational treatment and the patient’s investment in product technology and building the core alternative development and connect
Slide 16: Technology driven
Technology driven One integrated and automated technology platform For personal use only Realtime dental clinical decision & acceptance App-Nea Portal Data Bridge between medical & Devices dental Connectivity, big data & personalised medicine Clinical evidence Analytics Screening & diagnosis Reimbur
Slide 17: Outlook
Outlook For personal use only FY22 guidance Key considerations Key strategic objectives • Revenue growth of at least 15%2 • Continue to respond to Treatment focused • EBITDA1 break even as we invest for future changing market conditions • Focus on Medical Initiative in growth (expected to rebound in
Slide 18: Thank you
For personal use only Thank you © November 2021 SomnoMed